Mettler-Toledo (MTD) Gets a Buy from Barclays
Barclays analyst Luke Sergott maintained a Buy rating on Mettler-Toledo today and set a price target of $1,600.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Sergott is an analyst with an average return of -4.9% and a 39.02% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Illumina, Thermo Fisher, and Guardant Health.
In addition to Barclays, Mettler-Toledo also received a Buy from Stifel Nicolaus’s Daniel Arias in a report issued on November 10. However, on the same day, Robert W. Baird maintained a Hold rating on Mettler-Toledo (NYSE: MTD).
Based on Mettler-Toledo’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.03 billion and a net profit of $217.49 million. In comparison, last year the company earned a revenue of $954.54 million and had a net profit of $211.52 million
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MTD in relation to earlier this year. Most recently, in August 2025, Shawn Vadala, the CFO of MTD sold 300.00 shares for a total of $397,500.00.
Read More on MTD:
Disclaimer & DisclosureReport an Issue
- Mettler-Toledo price target raised to $1,500 from $1,450 at BofA
- Mettler-Toledo price target raised to $1,400 from $1,200 at Wells Fargo
- Mettler-Toledo price target raised to $1,600 from $1,450 at Stifel
- Mettler-Toledo price target raised to $1,444 from $1,342 at Baird
- Mettler-Toledo price target raised to $1,700 from $1,600 at Citi
